

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived mouse PD-L2/B7-DC protein		
	Mouse PD-L2 (Leu20-Arg219) (Lys113Ser) Accession # Q9WUL5	IEGRMD	Human IgG ₁ (Pro100-Lys330)
	N-terminus		C-terminus
N-terminal Sequence Analysis	Leu20		
Structure / Form	Disulfide-linked homodimer		
Predicted Molecular Mass	49 kDa		

SPECIFICATIONS

SDS-PAGE	64-84 kDa, reducing conditions
Activity	Measured by its binding ability in a functional ELISA. When Recombinant Mouse PD-L2/B7-DC (K113S) Fc Chimera is immobilized at 2 µg/mL (100 µL/well), Recombinant Mouse RGM-B (Catalog # 3597-RG) binds with an ED ₅₀ of 0.08-0.48 µg/mL. Recombinant Mouse PD-L2/B7-DC (K113S) Fc Chimera (Catalog #10021-PL) weakly binds to Recombinant Mouse PD-1.
Endotoxin Level	<0.10 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 500 µg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<ul style="list-style-type: none"> ● 12 months from date of receipt, ≤ -20 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 3 months, ≤ -20 °C under sterile conditions after reconstitution.

DATA

<p>Binding Activity</p> <p>When Recombinant Mouse PD-L2/B7-DC (K113S) Fc Chimera (Catalog # 10021-PL) is immobilized at 2 µg/mL, Recombinant Mouse RGMB (Catalog # 3597-RG) binds with an ED₅₀ of 0.08-0.48 µg/mL.</p>	<p>SDS-PAGE</p> <p>2 µg/lane of Recombinant Mouse PD-L2/B7-DC (K113S) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 64-84 kDa and 125-170 kDa, respectively.</p>
--	---

BACKGROUND

Programmed Death Ligand 2 (PD-L2), also known as Butyrophilin B7-DC, is a member of the B7 family of proteins that provide signals for regulating T-cell activation and tolerance (1). In humans, the mature PD-L2 consists of a 201 amino acid (aa) extracellular domain (ECD) with one V-like and one C-like Ig domain, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain (2, 3). Within the ECD, mouse PD-L2 shares 72% and 95% aa sequence identity with human and rat PD-L2, respectively. PD-L2 is expressed on dendritic cells, subsets of activated CD4⁺ and CD8⁺ T cells, and memory B cells that differentiate into plasma cells (3-5). At inflammatory sites such as rheumatoid arthritis, allergen exposure, and virus infection, PD-L2 is up-regulated on synoviocytes, infiltrating macrophages, dendritic cells, and airway epithelial cells (6-10). PD-L2, along with B7-H1/PD-L1, binds to T cell PD-1 where it promotes IFN-gamma production and CD40 Ligand up-regulation while inhibiting IL-4 production (2, 3, 11, 12). In addition, PD-L2 binds to repulsive guidance molecule family member b (RGMb) on macrophages and alveolar epithelial cells, supporting respiratory immune tolerance (13). Replacement of lysine residue at position 113 with serine (K113S) has been reported to result in a loss of binding capacity to PD-1, while retaining its T-cell stimulatory function through its interaction with RGMb (14). In asthma, PD-L2 suppresses IL-5 and IL-13 production, promotes IL-12 production by dendritic cells, and supports allergen-induced airway hyper-responsiveness and mucus production (8, 10).

References:

1. Ceeraz, S. *et al.* (2013) Trends Immunol. **34**:556.
2. Latchman, Y. *et al.* (2001) Nat. Immunol. **2**:261.
3. Tseng, S.Y. *et al.* (2001) J. Exp. Med. **193**:839.
4. Messal, N. *et al.* (2011) Mol. Immunol. **48**:2214.
5. Zuccarino-Catania, G.V. *et al.* (2014) Nat. Immunol. **15**:631.
6. Guo, G. *et al.* (2012) Clin. Rheumatol. **31**:271.
7. Loke, P. and J.P. Allison (2003) Proc. Natl. Acad. Sci. USA **100**:5336.
8. Matsumoto, K. *et al.* (2004) J. Immunol. **172**:2530.
9. Stanciu, L.A. *et al.* (2006) J. Infec. Dis. **193**:404.
10. Lewkowich, I.P. *et al.* (2013) Mucosal Immun. **6**:728.
11. Ghiotto, M. *et al.* (2010) Int. Immunol. **22**:651.
12. Shin, T. *et al.* (2003) J. Exp. Med. **198**:31.
13. Xiao, Y. *et al.* (2014) J. Exp. Med. **211**:943.
14. Nie, X. *et al.* (2017) Cell. Mol. Immunol. **14**:1.